Catalysis: Our Spotlight on Amolyt, Mediar and Violet
December 7, 2023
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
November 16, 2023
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
November 13, 2023
Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
November 8, 2023
Making Waves at Rippl: Quarterly CEO Update – November 2023
November 1, 2023
Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition
October 25, 2023
Rippl Care named to Top 50 emerging health IT vendors
October 5, 2023
ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer
October 4, 2023
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
September 12, 2023
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
August 17, 2023
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
July 17, 2023
Garuda Therapeutics Announces the Appointment of Giorgia Scapin, PhD, as Chief Scientific Officer
July 13, 2023
SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
May 10, 2023
Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism
May 2, 2023
Reintroducing Catalysis: Start-up News for the Mass General Brigham Community
April 19, 2023
Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets
April 4, 2023
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
March 15, 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
March 9, 2023
Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
February 7, 2023
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
January 6, 2023
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
January 5, 2023
Lyndra Therapeutics Announces New Board Members and Chief Technology Officer
January 05, 2023
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics
January 03, 2023
ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer
December 27, 2022
SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
December 15, 2022
SeQure Dx Emerges from Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies
November 16, 2022
ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma
November 15, 2022
Garuda Therapeutics Announces Appointment of David DiGiusto, PhD, as Chief Technology Officer
November 15, 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
October 18, 2022
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia
October 4, 2022
Abcuro Appoints Alex Martin as Chief Executive Officer
October 3, 2022
InStride Health Providing Virtual Pediatric Anxiety/OCD Treatment Launches with Support from McLean Hospital and Leading Healthcare Investors
October 3, 2022
New Mental Health Company to Revolutionize Mental Health Care Delivery for Seniors
September 28, 2022
Endpoints News Announces the 11 Most Promising Biotech Startups of 2022
September 22, 2022
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset
September 22, 2022
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program
September 12, 2022
Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study
September 12, 2022
Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022
September 12, 2022
Photys Therapeutics Debuts with $75 Million Series A Funding
September 8, 2022
Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
September 7, 2022
Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin
June 9, 2022
Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601
June 1, 2022
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies
May 18, 2022
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601
March 17, 2022
Garuda Therapeutics Announces Appointment of James Desiderio as Chief Regulatory Officer
March 15, 2022
Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, MD, to Board
March 8, 2022
Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601
March 1, 2022
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel
January 13, 2022
Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs
January 5, 2022
Scorpion Therapeutics Receives BioSpace NextGen Bio “Class of 2022” Recognition
January 5, 2022
Garuda thinks it has cracked the code to off-the-shelf stem cell transplants—and investors are betting $72 million to find out
September 23, 2021
Amolyt Pharma Announces $80 Million Series B Financing
September 16, 2021
Simon Sturge Joins Mediar Therapeutics as Executive Chairman
September 15, 2021
ROME Therapeutics Secures $77 Million in Series B Financing
September 14, 2021
Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough
August 31, 2021
Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
August 4, 2021
Gene Editing Analysis Firm SeQure Dx Closes $17.5M Series A Funding Round
August 3, 2021
Lyndra Therapeutics Completes $60.5 Million Series C Financing
June 24, 2021
Verve Therapeutics Announces Pricing of Initial Public Offering
June 16, 2021
Gene editing biotech Verve indicates a swift swerve onto Wall Street, asking for $100M IPO
June 1, 2021
Looking to reinvent those troubled AAVs you've been reading about, investors back a $110M reboot
April 30, 2021
Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment
April 18, 2021
Its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
March 22, 2021
Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments
March 17, 2021
Affinia Therapeutics Announces Addition of Gene Therapy
February 17, 2021
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline
January 19, 2021
Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0'
January 7, 2021
Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another
January 7, 2021
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
January 6, 2021
ZielBio Appoints Dieter Weinand Executive Chair
December 9, 2020
Amolyt Pharma Announces Research Collaboration with PeptiDream
December 8, 2020
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
November 12, 2020
Scorpion Therapeutics debuts with $108M to 'put the sting in cancer'
October 26, 2020
Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601
October 14, 2020
Walden Biosciences Launches to Transform the Treatment of Kidney Disease28
October 6, 2020
BIAL Goes Global w/ New US Research Center and Acquisition of Promising Parkinson's Disease Program
October 1, 2020
Nocion Therapeutics Advances to Clinical Stage and Expands Leadership
September 1, 2020
Verve Therapeutics Raises $63M to Advance Gene-Editing Therapies for Heart Diseases
June 11, 2020
Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds
June 11, 2020
3 months after its B round, Akouos files an IPO to the tune of $100M
June 8, 2020
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessi
April 27, 2020
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration
April 27, 2020
SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene
April 23, 2020
Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests
April 8, 2020
Akouos Closes $105 Million Series B Financing
March 3, 2020